Palisade Bio Inc. (PALI) Company Profile - Business Overview, Management Team & Corporate Information - Stocknear

Palisade Bio Inc.

NASDAQ: PALI · Real-Time Price · USD
0.90
0.13 (16.43%)
At close: Sep 26, 2025, 3:59 PM
0.86
-4.70%
After-hours: Sep 26, 2025, 07:23 PM EDT

Company Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract.

Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery.

The company was founded in 2005 and is headquartered in Carlsbad, California.

Palisade Bio Inc.
Palisade Bio Inc. logo
Country United States
IPO Date Mar 30, 2007
Industry Biotechnology
Sector Healthcare
Employees 8
CEO J. D. Finley

Contact Details

Address:
5800 Armada Drive
Carlsbad, California
United States
Website https://www.palisadebio.com

Stock Details

Ticker Symbol PALI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001357459
CUSIP Number 696389105
ISIN Number US6963894026
Employer ID 52-2007292
SIC Code 2836

Key Executives

Name Position
J. D. Finley Chief Executive Officer, Chief Financial Officer & Director
Dr. Mitchell Lawrence Jones M.D., Ph.D. Chief Operating Officer & Chief Medical Officer
Dr. Joerg Heyer Ph.D. Head of Translational Science & Medicine
Ryker Willie Senior Vice President of Finance & Corporate Controller

Latest SEC Filings

Date Type Title
Sep 18, 2025 8-K Current Report
Sep 15, 2025 DEF 14A Filing
Sep 15, 2025 ARS Filing
Sep 15, 2025 DEFA14A Filing
Sep 05, 2025 PRE 14A Filing
Sep 05, 2025 8-K Current Report
Sep 05, 2025 4 Filing
Sep 05, 2025 4 Filing
Sep 05, 2025 4 Filing
Sep 05, 2025 4 Filing